Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18384644 | 1.00 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384660 | 0.90 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384647 | 0.90 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384645 | 0.88 | KDM4E (0.40) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384661 | 0.81 | TSHR (0.44) | ALDH1A1HPGDMAPTNPSR1 | |
| SCHEMBL18384648 | 0.81 | TSHR (0.44) | ALDH1A1HPGDMAPTNPSR1 | |
| SCHEMBL18384650 | 0.80 | ROCK2 (0.38) | PDE4APDE4BPDE4CPDE4DROCK2 | |
| SCHEMBL18384664 | 0.77 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384651 | 0.77 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DMAOA | |
| SCHEMBL18384638 | 0.75 | KDM4E (0.41) | PDE4APDE4BPDE4CPDE4DPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934309-B2 | Tricyclic quinone derivative | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. | 2019-08-08 | — | — | US | disclosed |
| EP-3127907-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | Boston Biomedical, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | BOSTON BIOMEDICAL, INC. (US) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241583-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | PDE4A 3952/4885PDE4B 3741/4885PDE4C 3940/4885 |
| US-20170015677-A1 | NEW TRICYCLIC QUINONE DERIVATIVE | NQO1, SQOR, SULT1E1 | PDE4A 3952/4885PDE4B 3741/4885PDE4C 3940/4885 |
| US-10934309-B2 | Tricyclic quinone derivative | NQO1, NQO2, SQOR | PDE4A 4234/4885PDE4B 4106/4885PDE4C 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.